Incyte
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.
INCY Key Statistics
Stock Snapshot
As of today, Incyte(INCY) shares are valued at $106.88. The company's market cap stands at 20.85B, with a P/E ratio of 17.82.
On 2026-01-19, Incyte(INCY) stock moved within a range of $104.83 to $108.58. With shares now at $106.88, the stock is trading +2.0% above its intraday low and -1.6% below the session's peak.
Trading volume for Incyte(INCY) stock has reached 1.7M, versus its average volume of 2.36M.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.
Over the past 52 weeks, Incyte(INCY) stock has traded between a high of $112.29 and a low of $53.56.
INCY News
Advertisement Why Incyte (INCY) Is On Investors' Radar Today Incyte (INCY) is back in focus after recent share price moves and fresh attention on its pipeline...
Incyte (INCY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Incyte’s latest clinical update centers on a Phase 0 observa...
William Blair analyst Matt Phipps has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Claim 70% Off TipRanks Premium Unlock hedge...
Analyst ratings
46%
of 28 ratingsMore INCY News
Analyst Evan Seigerman from BMO Capital maintained a Sell rating on Incyte and keeping the price target at $75.00. Claim 70% Off TipRanks Premium Unlock hedge f...
TD Cowen raised the firm’s price target on Incyte (INCY) to $128 from $101 and keeps a Buy rating on the shares. The company presented a roadmap to potentially...
In early January 2026, Incyte reported positive topline Phase 3 frontMIND results showing that adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP i...